ArticleClinical rheumatology2026
Idiopathic granulomatous mastitis in the United Arab Emirates: a retrospective case series of clinical features, management, and outcomes.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic granulomatous mastitis (IGM) is a rare, chronic inflammatory breast disease that mimics infection and malignancy, with no standardized treatment approach.
methodsWe conducted a single center retrospective case series of 25 women with histopathologically confirmed IGM managed at a tertiary center in Dubai, UAE (June 2022-June 2025). Demographic, clinical, imaging, histopathological, treatment, and outcome data were analyzed. Remission was defined as complete clinical and radiological resolution sustained for at least 6 months after cessation of therapy. The median follow-up duration was 20 months.
resultsThe median age was 38 years; all patients were pre-or perimenopausal, and 92% (n = 23) had a history of breastfeeding. The most common presenting features were tenderness (92%, n = 23) and a palpable mass (88%, n = 22). Ultrasound frequently identified abscesses (60%, n = 15) and axillary lymphadenopathy (56%, n = 14), whereas mammography showed ductal dilatation (48%, n = 12) and solid masses (32%, n = 8). Histopathology demonstrated lobulocentric non-caseating granulomas in 72% (n = 18) and cystic neutrophilic granulomatous mastitis in 28% (n = 7) (n = 7), with overlapping abscess formation in 40% (n = 10). Medical therapy alone was used in 52% (n = 13) of patients and combined medical-surgical management in 48% (n = 12). Remission occurred in 69% (n = 9) of medically managed patients compared to 25% (n = 3) in the combined group.
conclusionIGM predominantly affected young, parous women and showed a heterogeneous clinical course. Medical management with corticosteroids, with or without disease-modifying anti-rheumatic drugs, appears to be associated with higher observed remission rates than combined surgical approaches. Early diagnosis and timely immunosuppressive therapy may reduce recurrence and avoid unnecessary surgery. Limitations include the small sample size, retrospective single-center design, and heterogeneity of treatment regimens. Key Points • Idiopathic granulomatous mastitis predominantly affected young, parous, premenopausal women with recent breastfeeding history. • Medical management with corticosteroids, with or without DMARDs, demonstrated higher observed remission rates than combined surgical approaches. • Surgical intervention was associated with greater complication burden, increased flares, and more chronic disease. • Early diagnosis and timely immunosuppressive therapy may improve outcomes while reducing unnecessary surgery.
Indexed as
Identifiers
42704583What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.